menu
    • menu
    [{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Diclofenac Epolamine","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Diclofenac Epolamine","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Patch","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Yaral Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Diclofenac Epolamine","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Yaral Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Yaral Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Yaral Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Diclofenac Epolamine","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"IBSA Institut Biochimique","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Diclofenac Epolamine","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Pfizer Inc \/ IBSA Institut Biochimique","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ IBSA Institut Biochimique"},{"orgOrder":0,"company":"Eversana","sponsor":"Yaral Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"Diclofenac Epolamine","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Eversana \/ Yaral Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Eversana \/ Yaral Pharma"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Diclofenac Epolamine","moa":"PTGS1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Diclofenac Epolamine

    Menu

    Diclofenac Epolamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eversana

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eversana

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Yaral Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Yaral Pharma Partners With EVERSANA to Support the Commercialization of Its Expanding Generics Portfolio

                            Details : Under the partnership, EVERSANA will support the expansion of its portfolio of pain and endocrinology products in the U.S., including Flector (diclofenac epolamine), a topical prescription therapy for acute pain due to minor strains, sprains, and contusi...

                            Product Name : Flector

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 22, 2023

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Yaral Pharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Yaral Pharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Yaral Pharma

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Yaral Pharma Launches Diclofenac Epolamine Topical System 1.3%

                            Details : Diclofenac epolamine topical system 1.3% is a prescription nonsteroidal anti-inflammatory (NSAID) medicated patch indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.

                            Product Name : Diclofenac Epolamine-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 03, 2023

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IBSA Institut Biochimique

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            IBSA Institut Biochimique

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants with Minor Soft Tiss...

                            Details : Licart (Diclofenac Epolamine) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Soft Tissue Injuries.

                            Product Name : Licart

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 29, 2021

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pfizer Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : IBSA Institut Biochimique

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            IBSA Reacquires Commercial Rights to the Flector® Brand in the US

                            Details : With the return of the commercial rights of Flector, a product that IBSA has developed, IBSA now offers two prescription topical drugs to treat acute pain due to minor strains, sprains, and contusions.

                            Product Name : Flector

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 12, 2021

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : IBSA Institut Biochimique

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Actavis Inc

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Actavis Inc

                            Ireland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

                            Details : Diclofenac Epolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ankle Injuries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 24, 2014

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            IBSA Institut Biochimique

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            IBSA Institut Biochimique

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries

                            Details : Diclofenac Hydroxyethylpyrrolidine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Athletic Injuries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 07, 2014

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pfizer Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain

                            Details : Diclofenac Epolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Back Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 22, 2010

                            Lead Product(s) : Diclofenac Epolamine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth